Nivolumab Perioperative Immunotherapy in EGFR-Positive Resectable NSCLC

Introduction to EGFR-Positive NSCLC Treatment

• The European Society for Medical Oncology (ESMO) explicitly states that immune checkpoint inhibitors as monotherapy are not recommended before other standard therapeutic options are exhausted in EGFR-mutant lung cancer 1
• The National Comprehensive Cancer Network (NCCN) guidelines recommend avoiding osimertinib within 3 months of immune checkpoint inhibitors due to significantly increased pneumonitis risk 2

Why Immunotherapy Should Be Avoided in EGFR-Positive Disease

• Immune checkpoint inhibitors demonstrate markedly inferior efficacy in EGFR-mutated NSCLC regardless of PD-L1 expression, with a response rate of only 3.6% compared to 23% in EGFR wild-type disease 1, 3, 4
• The response rate to PD-1/PD-L1 inhibitors in EGFR-mutated tumors is significantly lower than in EGFR wild-type disease 3, 4

Recommended Treatment Algorithm for EGFR-Positive Resectable NSCLC

• The American College of Surgeons recommends proceeding with complete surgical resection as the primary curative treatment for resectable stage IIIA disease, ensuring R0 (complete) resection with pathological confirmation of margins 5, 6
• The NCCN guidelines recommend initiating osimertinib as adjuvant therapy post-operatively, as it is the preferred first-line EGFR-TKI due to superior progression-free survival, overall survival, and CNS penetration 2
• Osimertinib achieves a CNS response rate of over 60% compared to first-generation TKIs 2

Management of Disease Progression

• If T790M mutation develops after first-line EGFR-TKI, the NCCN guidelines recommend switching to osimertinib, which achieves a 71% response rate and 93% disease control rate 7, 8
• For symptomatic systemic progression after osimertinib, the NCCN guidelines recommend using amivantamab-vmjw plus carboplatin and pemetrexed as a Category 1 preferred option for nonsquamous histology with multiple lesions 2

Critical Pitfalls to Avoid

• The ESMO guidelines recommend never delaying molecular testing results before initiating treatment planning, as EGFR mutation status fundamentally changes the treatment paradigm away from immunotherapy 1, 2
• The NCCN guidelines recommend avoiding combining EGFR-TKIs with immunotherapy due to excessive toxicity, particularly pneumonitis 1
• The NCCN guidelines recommend continuing EGFR-TKI therapy even after resistance develops when adding subsequent treatments, as discontinuation can lead to accelerated disease progression 7, 8